陈氏疱疹二号方治疗男性复发性生殖器疱疹缓解期阴虚邪恋证100例临床观察

Clinical Observation on 100 Cases of Male Recurrent Genital Herpes in Remission Stage of Yin Deficiency and Lingering Pathogen Syndrome Treated by Chenshi Paozhen Erhao Formula( 陈氏疱疹二号方)

目的观察陈氏疱疹二号方治疗男性复发性生殖器疱疹(RGH)缓解期阴虚邪恋证患者的临床疗效及可能机制。方法将160例男性RGH缓解期阴虚邪恋证患者随机分为治疗组106例和对照组54例。治疗组予陈氏疱疹二号方,每日1剂;对照组予阿昔洛韦片,每次0.4g,每日2次。两组疗程均为3个月,随访1年。观察两组患者治疗前后皮肤病损评分,观察治疗期间、随访6个月、随访1年。平均复发皮肤病损评分、复发频次及平均复发间隔时间,检测治疗前后外周血白细胞介素2(IL-2)、白细胞介素4(IL-4)、白细胞介素10(IL-10)、干扰素γ(IFN-γ)、CD4^+、CD8^+、CD4^+/CD8^+水平,并评价抗复发疗效及安全性。结果治疗期间两组患者均未出现复发。与治疗前比较,治疗后治疗组皮肤病损评分显著降低(P<0.001),且低于对照组(P<0.05)。随访6个月及随访1年治疗组平均复发皮肤病损评分、复发频次均低于同期对照组,平均复发间隔时间长于对照组(P<0.05)。治疗组抗复发总有效率为21.00%,高于对照组的8.00%(P<0.05)。与治疗前比较,治疗后治疗组外周血IL-2、IFN-γ、CD4^+、CD4^+/CD8^+水平显著升高,IL-4、IL-10、CD8^+水平显著降低(P<0.01)。治疗后治疗组外周血IL-2、IFN-γ、CD4^+、CD4^+/CD8^+水平高于对照组,IL-4、IL-10、CD8^+水平低于对照组(P<0.01)。两组患者治疗期间均未发生明显不良反应。结论陈氏疱疹二号方治疗男性RGH缓解期阴虚邪恋证患者疗效确切,能明显减少疾病复发次数,延长复发间隔,其作用机制可能是通过调节患者体内的免疫平衡,改善其免疫功能而发挥作用。

Objective To observe clinical efficacy of Chenshi Paozhen Erhao Formula(CPEF,陈氏疱疹二号方) in treatment of patients with male recurrent genital herpes(RGH) in remission stage of yin deficiency and lingering pathogen syndrome and its possible mechanism. Methods A total of 160 patients with RGH in remission stage of yin deficiency and lingering pathogen syndrome were randomly divided into treatment group(106 patients) and control group(54 patients). The treatment group was treated with CPEF with 1 dose per day, and the control group was treated with Aciclovir Tablets, with 0.4 g each time, twice a day. Both groups were treated for 3 months and followed up for 1 year. Skin lesion scores in the 2 groups were observed before and after the treatment. Average skin lesion scores, frequency of RGH recurrence and mean recurrence intervals were observed during the treatment period, follow-up period of 6 months and of 1 year. Levels of peripheral blood interleukin-2(IL-2), interleukin-4(IL-4), interleukin-10(IL-10), interferon-γ(IFN-γ), CD4^+, CD8^+ and CD4^+/CD8^+ were measured before and after the treatment. The anti-recurrence efficacy and safety were evaluated. Results There were no recurrences in both groups during the treatment period. The skin lesion score in the treatment group was significantly decreased after treatment(P<0.001), and it was lower than that in the control group(P<0.05). At 6-month follow-up and 1-year follow-up, the mean recurrent skin lesion score and the frequency of recurrence in the treatment group were lower than those in the control group during the same time, and the mean recurrence interval was longer than that in the control group(P<0.05). The anti-recurrence total effective rate in the treatment group was 21.00%, higher than that in the control group(8.00%,P<0.05). Levels of peripheral blood IL-2, IFN-γ, CD4^+ and CD4^+/CD8^+ in the treatment group were significantly increased, and levels of IL-4, IL-10 and CD8^+ were significantly decreased after treatment(P<0.01). After treatment, levels of peripheral blood IL-2, IFN-γ, CD4^+ and CD4^+/CD8^+ in the treatment group were higher than those in the control group, and the levels of IL-4, IL-10 and CD8^+ were lower than those in the control group(P<0.01). There were no significant adverse reactions during the treatment period in both groups. Conclusion CPEF is effective in the treatment of male patients with RGH in the remission stage of yin deficiency and lingering pathogen syndrome. It can significantly decrease the frequency of recurrence and prolong the recurrence interval. It may play a role by regulating immune balance of the patients and improving their immune function.